Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting.

被引：1
|
作者：
Ravindranathan, Deepak
Liu, Yuan
Martini, Dylan J.
Nazha, Bassel
Brown, Jacqueline T.
Russler, Greta
Yantorni, Lauren Beth
Caulfield, Sarah
Master, Viraj A.
Carthon, Bradley Curtis
Kucuk, Omer
Bilen, Mehmet Asim
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA
[3] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16570
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
    McGregor, Bradley Alexander
    Huang, Jiaming
    Xie, Wanling
    Xu, Wenxin
    Bilen, Mehmet Asim
    Braun, David A.
    Zhang, Tian
    McKay, Rana R.
    McDermott, David F.
    Hammers, Hans J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [23] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Razak, Albiruni R. A.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).
    Beckermann, Katy
    Campbell, Matthew T.
    Haas, Naomi B.
    Ornstein, Moshe Chaim
    Gao, Xin
    Mao, Shifeng S.
    Hammers, Hans J.
    George, Saby
    Nelson, Ariel Ann
    Gourdin, Theodore Stewart
    Keshava-Prasad, Holavanahalli
    Hussain, Arif
    Hoimes, Christopher J.
    Yan, Hongxia
    Esquibel, Vanessa
    McIntyre, Gail
    Geller, Robert B.
    Voss, Martin H.
    Rini, Brian I.
    Shah, Neil J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Peripheral immunomodulatory changes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab
    Almeida, Lorena
    Maia, Manuel
    Won, Haejung
    Moreira, Dayson
    Bergerot, Paulo
    Kortylewski, Marcin
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
    Keeler, Molika Emmeline
    Kessler, Elizabeth Riley
    Bernard, Brandon
    Weisdack, Sarah
    Breaker, Kathryn M.
    Wold, Mali
    Ertz, Donna
    Weitzenkamp, David
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
    De Velasco, G.
    Alonso-Gordoa, T.
    Rodriguez-Moreno, J. F.
    Duran, I.
    Carretero-Gonzalez, A.
    Martin-Soberon, M.
    Gutierrez Banos, J. L.
    Guerrero-Ramos, F.
    Duenas, M.
    Castellano Gauna, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S698 - S699
  • [29] A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab
    Brown, Landon
    Kinsey, Emily
    Kao, Chester
    Healy, Patrick
    Armstrong, Andrew
    McNamara, Megan
    Ramalingam, Sundhar
    Harrision, Michael
    George, Daniel
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)
    Verzoni, E.
    Ferro, S.
    Procopio, G.
    Cova, A.
    Ratta, R.
    Raimondi, A.
    Sepe, P.
    Squarcina, P.
    Lalli, L.
    Huber, V.
    Rinchai, D.
    Bedognetti, D.
    Rivoltini, L.
    ANNALS OF ONCOLOGY, 2018, 29
12345